OCC 1.16% 42.5¢ orthocell limited

Ann: Remplir Gains Australian Reimbursement, page-56

  1. 1,190 Posts.
    lightbulb Created with Sketch. 122
    A couple of points from this years AGM. It was the largest turnout of shareholders for a number of years, clearly interest is increasing.
    Suggestion that Striate would go from 3000 currently to 100000 over the next 3 years - I think this may be conservative. They have completed the modular extension to the facility at Murdoch that adds around another 300m2 of workspace. Bio Horizons is looking at February 2023 for their formal launch of Striate, watch out for this. A figure of around $350 was mentioned for Striate, this tally’s fairly well with the $400 mentioned for current membranes when I asked my dentist this week if he had heard of Striate (he had not but he did say his partner did the implant work and it is a rapidly growing field, also asked if he knew of Bio Horizons - there he said if they were handling the product they are great at service and marketing) he also said he would check it out.
    With Remlier is looking good for international acceptance -not surprisingly.
    Will break even on Australian revenue alone within 3 years.
    Tennis elbow study May 2023
    Expecting a significant rebate over the next 12 months
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.